Advancing Diagnosis and Treatment in People Living with HIV and Tuberculosis Meningitis.
Sarah KimudaDerrick KasoziSuzan NamombweJane GakuruTimothy MugabiEnock KagimuMorris K RutakingirwaKristoffer E LeonFelicia ChowSean WassermanDavid R BoulwareFiona V CresswellNathan C BahrPublished in: Current HIV/AIDS reports (2023)
The molecular assay GeneXpert MTB/Rif Ultra has improved sensitivity but has inadequate negative predictive value to "rule-out" TBM. Evaluations of tests focused on the host response and bacterial components are ongoing. Clinical trials are in progress to explore the roles of rifampin, fluoroquinolones, linezolid, and adjunctive aspirin. Though diagnosis has improved, novel modalities are being explored to improve the rapid diagnosis of TBM. Multiple ongoing clinical trials may change current therapies for TBM in the near future.
Keyphrases
- clinical trial
- pulmonary tuberculosis
- mycobacterium tuberculosis
- low dose
- phase ii
- emergency department
- randomized controlled trial
- hiv aids
- cardiovascular disease
- phase iii
- current status
- type diabetes
- antiplatelet therapy
- cardiovascular events
- double blind
- single molecule
- mass spectrometry
- loop mediated isothermal amplification
- acute coronary syndrome
- adverse drug
- atrial fibrillation
- sensitive detection
- electronic health record
- quantum dots